

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/754,547	01/12/2004	Longgui Wang	15741.004	9273	
7.	590 06/16	6	EXAMINER		
FENNEMORE CRAIG Suite 2600			JAGOE, DONNA A		
3003 N. Centra	l Avenue	ART UNIT	PAPER NUMBER		
Phoenix, AZ 85012			1614		
			DATE MAILED: 06/16/200	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	*			
		10/754,547	WANG ET AL.	·•			
	Office Action Summary	Examiner	Art Unit				
		Donna Jagoe	1614				
Period fo	The MAILING DATE of this communication a or Reply	appears on the cover sheet w	ith the correspondence addre	ess			
WHI(- Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REF CHEVER IS LONGER, FROM THE MAILING nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory perior to the reply within the set or extended period for reply will, by state reply received by the Office later than three months after the may ed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNION 1.1.136(a). In no event, however, may a residud will apply and will expire SIX (6) MON tute, cause the application to become AB	CATION. reply be timely filed ITHS from the mailing date of this comm BANDONED (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on						
		his action is non-final.		•			
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice unde	er <i>Ex par</i> te <i>Quayl</i> e, 1935 C.D). 11, 453 O.G. 213.				
Disposit	ion of Claims						
4)⊠	4)⊠ Claim(s) <u>1-34</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
-	5) Claim(s) is/are allowed.						
6)	6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) <u>1-34</u> are subject to restriction and/o	or election requirement.					
Applicati	on Papers						
9)[The specification is objected to by the Exami	iner.					
10)	The drawing(s) filed on is/are: a)☐ a	ccepted or b) objected to	by the Examiner.				
	Applicant may not request that any objection to the	he drawing(s) be held in abeyan	ice. See 37 CFR 1.85(a).				
_	Replacement drawing sheet(s) including the corre	,	• •	` '			
11)	The oath or declaration is objected to by the	Examiner. Note the attached	I Office Action or form PTO-	-152.			
Priority ι	ınder 35 U.S.C. § 119						
	Acknowledgment is made of a claim for forei ☐ All b) ☐ Some * c) ☐ None of:	gn priority under 35 U.S.C. §	119(a)-(d) or (f).				
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the pr	riority documents have been	received in this National Sta	age			
	application from the International Bure	, , , , , , , , , , , , , , , , , , , ,					
* 5	see the attached detailed Office action for a li	ist of the certified copies not	received.				
Attachmen	t(s)						
	e of References Cited (PTO-892)	4) Interview S	Summary (PTO-413)				
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s	s)/Mail Date	=2\			
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date	6) Notice of Ir	nformal Patent Application (PTO-15) /)			

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-30, drawn to a method of treating an inflammatory-related disease, classified in class 514, subclass 886.
- II. Claims 31-34, drawn to a pharmaceutical composition, classified in class514, subclass 414.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the method of treating an inflammatory related disease can be practiced with another materially different product, such as acetylsalicylic acid.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Claim1 is generic to the following disclosed patentably distinct species: (formula (I), formula (II) and formula (III) and in claims 33-34, formula (IV), (V) and (VI). The species are independent or distinct because the MPEP at § 803.02 states that an

Art Unit: 1614

application with a Markush-type claim drawn to the compound X-R, wherein R is a radical selected from the group consisting of A, B, C, D, and E, the examiner may require a provisional election of a single species, XA, XB, XC, XD, or XE. The Markush-type claim would then be examined fully with respect to the elected species and any species considered to be clearly unpatentable over the elected species. If on examination the elected species is found to be anticipated or rendered obvious by prior art, the Markush-type claim and claims to the elected species shall be rejected, and claims to the nonelected species would be held withdrawn from further consideration. Accordingly, applicant is required to elect a single compound structure, including side chains, for examination along with a statement as to which claims are encompassed by the elected structure.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Art Unit: 1614

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be **rejoined**.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process

Art Unit: 1614

claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

A telephone call to the attorney is not required where: 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the Examiner knows from past experience that a telephone election will not be made, see MPEP Sect. 812.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1614

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna Jagoe whose telephone number is (571) 272-0576. The examiner can normally be reached on Monday through Thursday from 9:00 A.M. - 3:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-27&-100%

Donna Jagoè /
Patent Examiner
Art Unit 1614

June 5, 2006

ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER

1) Marsho 6/11/06